Journal
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume 1875, Issue 1, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.bbcan.2020.188481
Keywords
miRNAs; Docetaxel resistance; Prostate cancer; Drug resistance; Taxane
Categories
Ask authors/readers for more resources
One of the main challenges in the treatment of metastatic prostate cancer is the development of resistance to docetaxel, the gold standard therapy. Non-coding RNA appears to play a significant role in the processes leading to docetaxel resistance.
One of the main problems with the treatment of metastatic prostate cancer is that, despite an initial positive response, the majority of patients develop resistance and progress. In particular, the resistance to docetaxel, the gold standard therapy for metastatic prostate cancer since 2010, represents one of the main factors responsible for the failure of prostate cancer therapy. According to the present knowledge, different processes contribute to the appearance of docetaxel resistance and non-coding RNA seems to play a relevant role in them. In this review, a comprehensive overview of the miRNA network involved in docetaxel resistance is described, highlighting the pathway/s affected by their activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available